References
- Global Burden of Disease Study 2013 CollaboratorsGlobal, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013Lancet2015386999574380026063472
- ChongHYTeohSLWuDBKotirumSChiouCFChaiyakunaprukNGlobal economic burden of schizophrenia: a systematic reviewNeuropsychiatr Dis Treat20161235737326937191
- KaneJMTreatment strategies to prevent relapse and encourage remissionTreatment strategies to prevent relapse and encourage remissionJ Clin Psychiatry200768Suppl 142730
- LindenmayerJPLiu-SeifertHKulkarniPMMedication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJ Clin Psychiatry200970799099619497244
- PerkinsDOPredictors of noncompliance in patients with schizophreniaJ Clin Psychiatry200263121121112812523871
- KaneJMStrategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studiesJ Clin Psychiatry200364Suppl 16344014680417
- EreshefskyLMascarenasCAComparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamicsJ Clin Psychiatry200364Suppl 161823
- BrissosSVeguillaMRTaylorDBalanzá-MartinezVThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisalTher Adv Psychopharmacol20144519821925360245
- KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol201013563564719941696
- JangSWooJFive Month-Persistent Extrapyramidal Symptoms following a Single Injection of Paliperidone Palmitate: A Case ReportClin Psychopharmacol Neurosci201715328829128783941
- InadaTYagiGMiuraSExtrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidolSchizophr Res2002572–322723812223254
- KimJHLeeBCParkHJAhnYMKangUGKimYSSubjective emotional experience and cognitive impairment in drug-induced akathisiaCompr Psychiatry200243645646212439833
- HelldinLPeuskensJVauthRTreatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophreniaTher Adv Psychopharmacol20155419420726301075
- GopalSLiuYAlphsLSavitzANuamahIHoughDIncidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studiesNeuropsychiatr Dis Treat201391381139224092977
- RemingtonGMamoDLabelleAA PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidoneAm J Psychiatry2006163339640116513859
- HoracekJBubenikova-ValesovaVKopecekMMechanism of action of atypical antipsychotic drugs and the neurobiology of schizophreniaCNS Drugs200620538940916696579
- HellandASpigsetOSerum Concentrations of Paliperidone After Administration of the Long-Acting Injectable FormulationTher Drug Monit201739665966229040230
- SamtaniMNGopalSGassmann-MayerCAlphsLPalumboJMDosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial dataCNS Drugs2011251082984521936586
- SusatiaFFernandezHHDrug-induced parkinsonismCurr Treat Options Neurol200911316216919364450
- VolkowNDDingYSFowlerJSDopamine transporters decrease with ageJ Nucl Med19963745545598691238
- TinazziMAntoniniABoviTClinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonismJ Neurol2009256691091519252795